In the second se

Docket No.: WIBL-P01-013 (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mootha et al.

Application No.: 10/560501

ippineution 1 to ... To / Do o o o 1

Filed: December 12, 2005

For: METHODS OF REGULATING
METABOLISM AND MITOCHONDRIAL

FUNCTION

Confirmation No.: 3194

Art Unit: 1614

Examiner: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant submits herewith copies of references BA and CA-CL1 in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WIBL-P01-013.

Dated: June 2, 2006

Respectfully submitted,

Ignacio Perez de la Cruz

Registration No.: 55,535 ROPES & GRAY LLP

One International Place Boston, Massachusetts 02110-2624 (617) 951-7000

(617) 951-7000 (617) 951-7050 (Fax)

Attorneys/Agents For Applicant



Application No. (if known): 10/560501

Attorney Docket No.: WIBL-P01-013

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on \_\_\_\_\_ June 2, 2006\_\_\_\_

Susan Lanney
Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (46 References) (3 pages) Copies of Cited References BA and CA-CL1) Return Receipt Postcard



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/P7	·0		Complete if Known		
000	Subject of form 1440/0011	•		Application Number	10/560501	
IN	<b>IFORMATION</b>	N DI	SCLOSURE	Filing Date	December 12, 2005 Vamsi Krishna Mootha	
S	TATEMENT	BY A	APPLICANT	First Named Inventor		
_				Art Unit	4 <del>614</del> 1632	
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned J. Hama	
Sheet 1 of 3		Attorney Docket Number	WIBL-P01-013			

	U.S. PATENT DOCUMENTS							
Examiner		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where			
initials*	Cite No.1	Number-Kind Code <sup>2</sup> ( If known)	MM-DD-YYYY		Relevant Passages or Relevant Figures Appear			
/JH/	AA	US-2002/0049176	04-25-2002	Anderson				
1	AB	US-2002/0064773	05-30-2002	Herrnstadt				
	AC	US-2002/0127536	09-12-2002	Aprille				
	AD	US-5,602,009	02-11-1997	Evans et al.				
	AE	US-6,453,242-B1	09-17-2002	Eisenberg et al.				
1/	AF	US-6,511,808	01-28-2003	Wolffe et al.				
W	AG	US-6,607,882	08-19-2003	Cox, III et al.				

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°					
/JH/	ВА	WO-03/068944	08-21-2003	Dana-Farber Cancer Institute, Inc.							

\*EXAMNER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered, include copy of this form with next communication to applicant. \*Applicants unique cliation designation number (optional).\* See Khots Costs of USPPO Resets Conformation and Communication (and the Communication optional and Communi

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/JH/	CA	BATCHELOR, A.H., et al., "The Structure of GABP Alpha/Beta: An ETS Domain-Ankyrin Repeat Heterodimer Bound to DNA," Science, 279(5353):1037-1041 (1998).	
	CB BJORNTORP, P., et al., "Respiration and Phosphorylation of Mitochondria Isolated fro Skeletal Muscle of Diabetic and Normal Subjects," Diabetologia, 2:346-352 (1966).		
	СС	CHINENOV, Y., et al., "Isolation of a bi-directional promoter directing expression of the mouse GABPα and ATP synthase coupling factor 6 genes," Gene, 261:311-320 (2000).	
	CD	EISEN, M.B., et al., "Cluster analysis and display of genome-wide expression patterns," PNAS, 95:14863-14868 (1998).	Γ
T	CE	ERIKSSON, K.F., et al., "Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases," Diabetologia, 33:526-531 (1990).	
	CF	GOLUB, T.R., et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring," Science, 286(5439):531-537 (1999).	
	CG	HARA, K., et al., "A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes," Diabetologia, 45:740-743 (2002).	
V	СН	HERZIG, S., et al., "CREB regulates hepatic gluconeogenesis through the coactivator PGC-1," Nature, 413:179-183 (2001).	

Date

Considered

Examiner

Signature

PTC/SB/08a/b (07-05)
Approved for use through 97/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid CMB control number. Under the Paperwork Reduction Act of 1995, no persons

Sub	stitute for form 1449A/B/PT	0		Complete if Known		
				Application Number	10/560501	
- IN	<b>IFORMATION</b>	I DI	SCLOSURE	Filing Date	December 12, 2005	
S	TATEMENT B	3Y A	APPLICANT	First Named Inventor	Vamsi Krishna Mootha	
				Art Unit	1614	
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	WIBL-P01-013	

/JH	CI	HUSS, J.M., et al., "Peroxisome Proliferator-activated Receptor Coactivator-1α (PGC-1α) Coactivates the Cardiac-enriched Nuclear Receptors Estrogen-related Receptor-α and -y." J.	
7011	"	Biological Chemistry, 277(43):40265-40274 (2002).	
_	C.		-
	"	Extended Half-Site Sequences Including One Contained within Estrogen-Response	1
		Elements," Mol. Endocrinol., 11:342-352 (1997).	
	C		$\neg$
1 1	- 1	expression induces a high-energy expenditure and antagonizes obesity," PNAS,	
11		100(21):12378-12383 (2003).	
П	CI		,
l	- 1	of Hypotheses, with an Application to Gene Expression Data," Biometrical Journal, 44(7):789-	
ш	$\perp$	800 (2002).	
	CI		
$\perp$	-	(2000).	_
	CI		
⊢		fibres," Nature, 418:797-801 (2002).	_
	C	LIU, G., et al., "Net Affx: Affymetrix probesets and annotations," Nucleic Acids Research, 31(1):82-86 (2003).	
	CI		
1 1		Related Receptor α," Molecular and Cellular Biology, 23(22):7947-7956 (2003).	1
	C		
		128 (2000).	_
1 1	CI		
ш		deficiency by integrative genomics," PNAS, 100(2):605-610 (2003).	
ll	C		1
⊢⊢		coordinately downregulated in human diabetes," Nature Genetics, 34(3):267-273 (2003).	-
1 1	C.	PATTI, M.E., et al., "Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1," PNAS, 100(14):8466-	
		8471 (2003).	
$\vdash$	CI		-
1 1	0	Resistance," 300(5622):1140-1142 (2003).	
$\vdash$	C		
1 1	ľ	Adaptive Thermogenesis," Cell, 92:829-839 (1998).	
	C		
1	- 1	1a): Transcriptional Coactivator and Metabolic Regulator," Endocrine Reviews, 24(1):78-90	
1 1		(2003).	
	C:		П
		Increases in Levels of Peroxisome Proliferator-Activated Receptor-y Coactivator-1 and	
1		Peroxisome Proliferator-Activated Receptor-α in Skeletal Muscle," Diabetes, 52:2874-2881	
$\vdash$		(2003).	_
1	C,		
⊢⊦	C	biogenesis," Biochimica et Biophysica Acta, 1576:1-14 (2002).  SCHARFE, C., et al., "MITOP, the mitochondrial proteome database: 2000 update," Nucelic	_
	10	Acids Research, 28(1):155-158 (2000).	
	/ c.		_
ΙV	,	and Activity of the Orphan Nuclear Receptor Estrogen-Related Receptor α (ERR α)," J.	
<u> </u>	_	land Activity of the Ciphan Hadical Receptor Estroger Netated Receptor & (ERRA), 5.	

Date Considered

Examiner Signature

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1614

## Under the Paperwork Reduction Act of 1995, no persons are req d to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/B/PTO Complete if Known Application Number 10/560501 INFORMATION DISCLOSURE Filing Date December 12, 2005 STATEMENT BY APPLICANT First Named Inventor Vamsi Krishna Mootha

(Use as many sheets as necessary)

of

3

Sheet

Art Unit Examiner Name Not Yet Assigned WIBL-P01-013 3 Attorney Docket Number

		D	_
		Biological Chemistry, 278(11):9013-9018 (2003).	_
/JH/	CB1	SIMONEAU, J.A., et al., "Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women," FASEB J., 9:273- 1278 (1995).	
***************************************	CC1	SREEKUMAR, R., et al., "Gene Expression Profile in Skeletal Muscle of Type 2 Diabetes and the Effect of Insulin Treatment," Diabetes, 51:1913-1920 (2002).	
	CD1	STOREY, J.D., "A direct approach to false discovery rates," J.R. Statist. Soc. B, 64(3):479-498 (2002).	
	CE1	SU, A.I., et al., "Large-scale analysis of the human and mouse transcriptomes," PNAS, 99(7):4465-4470 (2002).	
	CF1	TAMAYO, P., et al., "Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation," PNAS, 96:2907-2912 (1999).	
	CG1	TAYLOR, S.W., et al., "Characterization of the human heart mitochondrial proteome," Nature Biotechnology, 21:281-286 (2003).	
	CH1	TUSHER, V.G., et al., "Significance analysis of microarrays applied to the ionizing radiation response," PNAS, 98(9):5116-5121 (2001).	
	CI1	VIRBASIUS, J.V., et al., "Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: A potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis," PNAS, 91:1309-1313 (1994).	
	CJ1	WU, Z., et al., "Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1," Cell, 98:115-124 (1999).	
	CK1	YANG, X., et al., "Microarray profiling of skeletal muscle tissues form equally obese, non- diabetic insulin-sensitive and insulin-resistant Pima Indians," Diabetologia, 45:1584-1593 (2002).	
	CL1	YOON, J.C., et al., "Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1," Nature, 413:131-138 (2001).	

<sup>\*</sup>EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Joanne Hama/	Date Considered	06/05/2008

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.